A small drug developer has initiated a second legal action against the U.S. Patent and Trademark Office (USPTO), challenging the agency’s recent refusal to patent a new dosage form of a drug used to treat low blood pressure. The case has been filed in the Virginia federal court, continuing the company’s effort to secure patent protection for its product. For more detailed information, refer to the original article here.